SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a significant surge following a strong earnings report that beat expectations, fueling community debate over whether the stock is a long-term turnaround play or an overextended bubble prone to a sharp reversal. Investors are actively discussing the potential for a massive short squeeze and debating the impact of government-backed foundry strategies as the stock tests multi-year highs.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are rallying in sympathy with Intel's strong earnings results, as investors express renewed confidence in the broader AI-driven CPU demand cycle. The community is actively debating the stock's parabolic trajectory and aggressive analyst upgrades, with many bullish traders focused on long-term data center growth while skeptical bears highlight concerns over overvaluation.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk Inc. (TTD) is trending following a spike in interest around a potential short squeeze, fueled by a recent Barron's article highlighting the stock's significant short position. The community remains sharply divided, with bulls pointing to a major insider stock purchase by the CEO and ongoing rumors of an OpenAI partnership, while bears argue the company is facing structural obsolescence and management concerns that keep the stock tethered to its multi-year lows.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The community is actively debating the sustainability of the semiconductor sector's parabolic rally, with many traders using $SOXS as a tactical hedge against perceived overextension and AI-driven euphoria. Amidst heavy volume, market participants are split between those betting on a major blow-off top and others warning that the instruments structural decay makes it a dangerous hold during sustained periods of upward sector momentum.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing a massive, sentiment-driven rally fueled by intense AI-related demand and speculative retail trading. Investors are actively debating whether this sector momentum represents a legitimate semiconductor 'super cycle' or an unsustainable bubble prone to a violent correction.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing significant market volatility and high trading volume following a major jury verdict that awarded the company hundreds of millions in damages over deceptive advertising practices by a competitor. The community is actively debating the stock's future, weighing the potential for a massive short squeeze against concerns over the timeline for legal payouts and long-term business fundamentals.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is rallying strongly following the company's strategic unveiling of its first AGI CPU, which marks a significant shift into in-house silicon design for data centers and heightened competition with major industry players. Investors are actively discussing the stock's transition from an IP licensor to a direct hardware competitor, while community sentiment remains split between excitement over the potential for massive AI-driven valuation expansion and concerns regarding the sustainability of the stock's high trading multiples.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as retail and institutional investors debate whether the sector is experiencing a historic AI-driven bull run or a dangerous bubble fueled by speculative circular financing. While many community members highlight the ETF's aggressive momentum and its role as a market leader, skeptics are expressing concern over overvaluation, supply chain bottlenecks, and increasing data center project delays.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to a major strategic partnership with OpenAI, which aims to accelerate drug discovery and optimize operational efficiency, alongside recent positive regulatory and data developments for its GLP-1 portfolio. The community remains focused on the company's valuation gap compared to its primary competitor, Eli Lilly, while actively debating the long-term impact of its oral Wegovy pipeline versus emerging rival therapies.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is seeing high volatility and heavy volume as traders react to the stock's significant gap up following an earnings report that featured a revenue beat and upward-revised guidance. The community is actively debating the sustainability of this momentum, with some investors eyeing technical breakout patterns while others prepare for a potential pullback after the rapid price appreciation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

LLY Stock Clings To 200-DMA As Sell-off Deepens: Retail Eyes ‘Positioning' Play Ahead Of Q1 Earnings Next Week

While Eli Lilly’s shares have been on a decline since March, analysts see strong upside as focus turns to its first-quarter earnings.

LLY Stock Slides Toward Sixth Weekly Loss, But 200-DMA Holds Firm: Is It Setting Up For Earnings Run?

Equity

<ul class="summary-bullets"><li>The brokerage believes Hims &amp; Hers' recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns.</li><li>JPMorgan sees positives in steadier GLP-1 business, progress toward peptide legalization, revenue rebound in the second half, and the potential for additional branded partnerships.</li><li>Hims &amp; Hers expanded its GLP-1 offerings on its platform to include Eli Lilly drugs, including Zepbound, Mounjaro, and Foundayo.</li></ul>Shares of Hims &amp; Hers Health (HIMS) rose about 4% in pre-market trading on Friday after a bullish brokerage note highlighted the company’s recent partnership with Novo Nordisk, boosting optimism around its expanding GLP-1 weight-loss offerings amid intensifying competition in the space.<a href="https://stocktwits.com/symbol/HIMS">HIMS shares</a> closed lower for a third consecutive session on Thursday, declining more than 9% during the sell-off.<h2 class="st-heading-2">HIMS-NOVO Partnership Removes Key Legal Overhang</h2>JPMorgan initiated coverage of Hims &amp; Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly. This represents a near 25% upside from the stock’s closing price on Thursday.Analyst Cory Carpenter believes Hims &amp; Hers recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns and positioning the company as a broader platform spanning branded, generic, and compounded offerings.In March, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">teamed</a> up with Hims &amp; Hers, allowing the telehealth platform to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices, while discontinuing the promotion of compounded GLP-1 drugs.This came after Novo sued Hims &amp; Hers for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug.<h2 class="st-heading-2">Analyst Sees Compelling Path For Upside</h2>The brokerage noted that the company has built a leading direct-to-consumer healthcare platform, serving around 2.5 million subscribers across areas such as weight loss, women’s health, erectile dysfunction, hair loss, testosterone, and an expanding presence in international markets.Carpenter stated that a steadier GLP-1 business, progress toward peptide legalization, an expected revenue rebound in the second half, and the potential for additional branded partnerships together create a “compelling catalyst path” for upside.Hims &amp; Hers also <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-lilly-zepbound-mounjaro-foundayo-novo-ceo-netflix-early-days/cZBfUtmReRh">expanded</a> its GLP-1 offerings on its platform to include Eli Lilly drugs such as Zepbound, Mounjaro, and Foundayo.However, HIMS is facing intensifying competition after Amazon expanded its GLP-1 management program through its One Medical platform, while rival telehealth platform Ro introduced major price cuts to its weight-loss membership program.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, while message volumes remained ‘extremely high.’One user said HIMS’ chart is intact and the stock could climb to “at least” $40.<stembedurl>https://stocktwits.com/Biofocuses/message/651242376</stembedurl>Another user noted that the short float is still high.<stembedurl>https://stocktwits.com/Hognose/message/651248357</stembedurl>The stock has shed around 17% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gets Pre-Market Boost – JPMorgan Initiation Flags ‘Turning Point’ With Novo Nordisk

JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly.

After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path

Smith Salley Wealth Management Buys 1,519 Shares of Eli Lilly and Company $LLY

Smith Salley Wealth Management boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,974 shares of the company's stock after buying an additional 1,519 shares d...

Eli Lilly and Company $LLY is Journey Advisory Group LLC's 9th Largest Position

Journey Advisory Group LLC decreased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,055 shares of the company's stock af...

Eli Lilly and Company $LLY Shares Sold by Silphium Asset Management Ltd

Silphium Asset Management Ltd lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 50.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,385 shares of the company's stoc...

TD Waterhouse Canada Inc. Grows Stock Holdings in Eli Lilly and Company $LLY

TD Waterhouse Canada Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 93,626 shares of the company's stock after acquiring an additional 5,31...

<ul class="summary-bullets"><li>Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.</li><li>Regeneron will lower the Medicaid prices of its products to match those in other developed nations.</li><li>REGN commits $9 billion in domestic R&amp;D and manufacturing capacity.</li></ul>Regeneron Pharmaceuticals (REGN) on Thursday became the 17th and the final biopharma firm to sign Trump’s drug pricing agreement, which is a pledge to lower the cost of current and future life-altering medications.&nbsp;The deal commits Regeneron to lower prices on its current and future medicines for Medicaid patients to match the lowest rates paid in other developed nations. As part of the pact, the company will sell its blockbuster cholesterol drug Praluent for $225 — down from roughly $537 — through the TrumpRx.gov direct-to-consumer platform."For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation — effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.&nbsp;“Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation.”&nbsp;Regeneron is the last of the original 17 pharmaceutical companies that received letters from Trump in July 2025, urging them to lower drug prices in the U.S. to levels paid by other developed nations.&nbsp;Companies that have already signed similar agreements include AbbVie, Amgen, AstraZeneca, Eli Lilly, GSK and Sanofi.<h2 class="st-heading-2">Otarmeni Approval And Sale</h2>REGN on Thursday also announced that its gene therapy for genetic hearing loss, Otarmeni, received accelerated approval from the U.S. Food and Drug Administration (FDA), and the firm will be providing the treatment free of cost to Americans.&nbsp;As part of the MFN agreement, Regeneron will not be subject to future pricing mandates and will receive three years of tariff relief through an agreement with the U.S. Department of Commerce. The company also committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.<h2 class="st-heading-2">What is Trump’s MFN</h2>The&nbsp;Most-Favored-Nation (MFN) policy is a signature healthcare initiative of the Trump administration designed to ensure that Americans do not pay more for prescription drugs than patients in other developed countries.Participating companies agree to offer deeply discounted pricing on drugs supplied to Medicaid and through the TrumpRx.gov platform.<h2 class="st-heading-2">Retail Take</h2>Retail sentiment on Stocktwits&nbsp;around REGN stock was ‘bullish’ with ‘high’ message volumes.&nbsp;One user highlighted he was bullish on REGN and UNH shares.&nbsp;<stembedurl>https://stocktwits.com/DrAzevedo/message/616338118</stembedurl> The stock lost 0.8% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

REGN becomes the final of the 17 drugmakers contacted by President Trump last year to sign his most favored nation (MFN) pricing agreement. 

Eli Lilly looks beyond GLP-1s with a $3 billion cancer buy

Eli Lilly announced it will acquire Kelonia Therapeutics for $3.25 billion upfront to expand its oncology and genetic medicines pipeline...

Top Medical Stocks To Keep An Eye On - April 23rd

Thermo Fisher Scientific, UnitedHealth Group, Boston Scientific, Danaher, and Eli Lilly and Company are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical...

Pharmaceutical Stocks Worth Watching - April 23rd

Eli Lilly and Company, AbbVie, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Current Price	$887.30
Prev Close	$917.65
Open	$899.78
Dividend Yield	0.56%
50-Day Moving Average	$963.62
Beta	0.71
Avg. Volume	2.82M
PE Ratio	40.62

52-Week High	$1,133.95
52-Week Low	$623.78
Market Capitalization	$867.01B
EPS (Annual)	$22.95
Price to Book	32.67
Revenue Per Employee	$1.3M

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LLY News

LLYLilly(Eli) & Co